COVID-19 inactive vaccine + recombinant human adenovirus serotype number 26 + mRNA vaccine

This entry refers to a comparative study group of three distinct COVID-19 vaccines evaluated in a multi-center observational clinical trial (NCT04895007) sponsored by Karamanoğlu Mehmetbey University. The group includes **CoronaVac** (an inactivated SARS-CoV-2 vaccine developed by Sinovac), **Sputnik V** (specifically the recombinant human adenovirus serotype 26 component, rAd26, developed by the Gamaleya Research Institute), and **BNT162b2** (an mRNA vaccine developed by Pfizer and BioNTech). The study aims to compare the long-term antibody responses (IgG and neutralizing antibodies) and disease progression across these different vaccine modalities—inactivated virus, viral vector, and mRNA—in a population of approximately 1,500 participants. All three vaccines are indicated for the prevention of COVID-19 and function by presenting or inducing the expression of the SARS-CoV-2 spike protein to elicit protective immunity.

Brand names

CoronaVacSputnik VComirnaty

Other names

Inactive Vaccinerecombinant human adenovirus serotype number 26mRNA VaccinerAd26 of Sputnik VrAd-26 of Sputnik VrAd 26 of Sputnik V